S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   191.69 (-0.96%)
AAPL   236.41 (+0.48%)
FB   185.85 (-2.38%)
MSFT   137.41 (-1.63%)
GOOGL   1,244.41 (-0.67%)
AMZN   1,757.51 (-1.68%)
CGC   20.21 (-2.65%)
NVDA   190.49 (-1.96%)
BABA   169.13 (-4.37%)
GE   8.96 (-0.88%)
TSLA   256.95 (-1.92%)
AMD   30.97 (-0.55%)
T   38.47 (+1.75%)
BAC   30.35 (+0.30%)
GILD   64.91 (-0.49%)
DIS   130.89 (-1.12%)
S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   191.69 (-0.96%)
AAPL   236.41 (+0.48%)
FB   185.85 (-2.38%)
MSFT   137.41 (-1.63%)
GOOGL   1,244.41 (-0.67%)
AMZN   1,757.51 (-1.68%)
CGC   20.21 (-2.65%)
NVDA   190.49 (-1.96%)
BABA   169.13 (-4.37%)
GE   8.96 (-0.88%)
TSLA   256.95 (-1.92%)
AMD   30.97 (-0.55%)
T   38.47 (+1.75%)
BAC   30.35 (+0.30%)
GILD   64.91 (-0.49%)
DIS   130.89 (-1.12%)
Log in

Milestone Pharmaceuticals Stock Price, News & Analysis (NASDAQ:MIST)

$20.85
+1.90 (+10.03 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$18.88
Now: $20.85
$20.99
50-Day Range
$16.14
MA: $20.55
$23.42
52-Week Range
$15.09
Now: $20.85
$27.95
Volume1,431 shs
Average Volume5,375 shs
Market Capitalization$510.62 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina. The company was founded in 2003 and is headquartered in Montréal, Canada.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MIST
CUSIPN/A
CIKN/A
Phone514-336-0444

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees20
Market Cap$510.62 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive MIST News and Ratings via Email

Sign-up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter.


Milestone Pharmaceuticals (NASDAQ:MIST) Frequently Asked Questions

What is Milestone Pharmaceuticals' stock symbol?

Milestone Pharmaceuticals trades on the NASDAQ under the ticker symbol "MIST."

How were Milestone Pharmaceuticals' earnings last quarter?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) announced its quarterly earnings data on Tuesday, August, 13th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.57. View Milestone Pharmaceuticals' Earnings History.

When is Milestone Pharmaceuticals' next earnings date?

Milestone Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Milestone Pharmaceuticals.

What price target have analysts set for MIST?

5 brokerages have issued twelve-month target prices for Milestone Pharmaceuticals' shares. Their forecasts range from $26.50 to $32.00. On average, they anticipate Milestone Pharmaceuticals' stock price to reach $30.10 in the next year. This suggests a possible upside of 44.4% from the stock's current price. View Analyst Price Targets for Milestone Pharmaceuticals.

What is the consensus analysts' recommendation for Milestone Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Milestone Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Milestone Pharmaceuticals.

Has Milestone Pharmaceuticals been receiving favorable news coverage?

Press coverage about MIST stock has trended negative on Friday, according to InfoTrie. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Milestone Pharmaceuticals earned a news impact score of -2.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Milestone Pharmaceuticals.

Are investors shorting Milestone Pharmaceuticals?

Milestone Pharmaceuticals saw a decline in short interest in the month of September. As of September 30th, there was short interest totalling 15,200 shares, a decline of 19.1% from the August 30th total of 18,800 shares. Based on an average daily trading volume, of 10,100 shares, the days-to-cover ratio is presently 1.5 days. Approximately 0.1% of the shares of the company are short sold. View Milestone Pharmaceuticals' Current Options Chain.

Who are some of Milestone Pharmaceuticals' key competitors?

What other stocks do shareholders of Milestone Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Milestone Pharmaceuticals investors own include Aeglea Bio Therapeutics (AGLE), ADMA Biologics (ADMA), Aqua Metals (AQMS), eHealth (EHTH), Evolus (EOLS), Iovance Biotherapeutics (IOVA), Intuitive Surgical (ISRG), Opko Health (OPK), Amneal Pharmaceuticals (AMRX) and Amarin (AMRN).

Who are Milestone Pharmaceuticals' key executives?

Milestone Pharmaceuticals' management team includes the folowing people:
  • Mr. Joseph G. Oliveto, CEO, Pres & Director (Age 51)
  • Dr. Philippe Douville, Founder & Chief Scientific Officer (Age 57)
  • Mr. Timothy L. Maness, VP of Fin. (Age 59)
  • Dr. Francis Plat, Chief Medical Officer (Age 61)
  • Mr. Lorenz Muller, Chief Commercial Officer (Age 55)

When did Milestone Pharmaceuticals IPO?

(MIST) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

When does Milestone Pharmaceuticals' lock-up period expire?

Milestone Pharmaceuticals' lock-up period expires on Tuesday, November 5th. Milestone Pharmaceuticals had issued 5,500,000 shares in its public offering on May 9th. The total size of the offering was $82,500,000 based on an initial share price of $15.00. After the expiration of Milestone Pharmaceuticals' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

How do I buy shares of Milestone Pharmaceuticals?

Shares of MIST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Milestone Pharmaceuticals' stock price today?

One share of MIST stock can currently be purchased for approximately $20.85.

How big of a company is Milestone Pharmaceuticals?

Milestone Pharmaceuticals has a market capitalization of $510.62 million. Milestone Pharmaceuticals employs 20 workers across the globe.View Additional Information About Milestone Pharmaceuticals.

What is Milestone Pharmaceuticals' official website?

The official website for Milestone Pharmaceuticals is http://www.milestonepharma.com/.

How can I contact Milestone Pharmaceuticals?

Milestone Pharmaceuticals' mailing address is 1111 DR. FREDERIK-PHILIPS BLVD SUITE 420, MONTREAL A8, H4M 2X6. The company can be reached via phone at 514-336-0444 or via email at [email protected]


MarketBeat Community Rating for Milestone Pharmaceuticals (NASDAQ MIST)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  19 (Vote Outperform)
Underperform Votes:  21 (Vote Underperform)
Total Votes:  40
MarketBeat's community ratings are surveys of what our community members think about Milestone Pharmaceuticals and other stocks. Vote "Outperform" if you believe MIST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MIST will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel